Artigo

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL¿17 and IL¿23 Inhibitors: A Retrospective, Multinational, Multicentre Study

André Vicente Esteves de Carvalho

ORIGINAL RESEARCH ARTICLE, v. 14, n. 1, p. 333-342, 2024.

Motivo: Produção Corpo Clínico

Setor HMV: Clínica Médica

Área da saúde: Dermatologia

Resumo: Abstract Background Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical trials and real-world studies suggests that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis reactivation.

Envie um e-mail para os autores